The Essential

GMO to Investors: Stop Gambling With Your Assets

The asset manager makes the case that while growth is fun, value pays off in the long run.

Biotech Surge Sends Averill to the Top of February’s Market Winners

A rebound in life‑sciences stocks — and a breakout Veradermics IPO — helped Averill’s funds notch some of the sector’s strongest gains last month.

Sponsored

Three Forces Shaping Copper's Path Forward

Space Race Explodes Faster Than Expected: ‘We're Going to Look Back on This Era as Historic’ 

Chris Davenport explains how a rapidly consolidating private market dominated by a few companies is redefining costs, capabilities, and risks for the U.S. space enterprise.

Related Content

GMO: There’s Joy in Missing Out

Julie Segal

Why Is No One Listening to Jeremy Grantham?

Christine Idzelis

Job Board – For Investors Only

Investment Analyst
​

University of Virginia

​
Learn More

Investment Analyst
​

DUMAC Inc

​
Learn More

Investment Analyst
​

DUMAC Inc

​
Learn More

Investment Analyst
​

BlueCross BlueShield Association

​
Learn More

1270 Avenue of the Americas, Suite 1120

New York, NY 10020

 

© Institutional Investor, LLC. All material subject to strictly enforced copyright laws. Please read our Terms and Conditions and Privacy Policy before using the site.

 

| Unsubscribe

LinkedIn
X
Bluesky
Instagram